EUVIMEDEUVIMED entdecken
Crossref

Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System

Tung S Tran iD, Duc V Le, Jena C Jacobs, Trang M Nguyen, David A Wetter, Giang H Nguyen

International Journal of Dermatology · 2026-04 · 65 (4) · 825-827

DOI: 10.1111/ijd.70082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 24.09.2025. Verfasst von Tung S Tran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hanoi Medical University, Hanoi, Vietnam. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The authors declare no conflicts of interest. Data supporting this study are available upon reasonable request to the corresponding author.

Schlagwörter

Stichwörter der Autor:innen

FAERS databaseadverse eventsanti‐IL‐17A/Fbimekizumabpharmacovigilance study

Autor:innen und Institutionen

  • Hanoi Medical University, Hanoi, Vietnam.
  • National Hospital of Dermatology and Venereology, Hanoi, Vietnam.
  • Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Bassett Medical Center, Cooperstown, New York, USA.

ORCID-Profile: Tung S Tran

Zitieren

APA

Tran, T. S., Le, D. V., Jacobs, J. C., Nguyen, T. M., Wetter, D. A., & Nguyen, G. H. (2026). Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. International Journal of Dermatology, 65(4), 825-827. https://doi.org/10.1111/ijd.70082

Vancouver

Tran TS, Le DV, Jacobs JC, Nguyen TM, Wetter DA, Nguyen GH. Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System. International Journal of Dermatology. 2026;65(4):825-827. doi:10.1111/ijd.70082

BibTeX
@article{Tran2026,
  author = {Tran, Tung S and Le, Duc V and Jacobs, Jena C and Nguyen, Trang M and Wetter, David A and Nguyen, Giang H},
  title = {Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {4},
  pages = {825--827},
  doi = {10.1111/ijd.70082}
}
Kostenlos starten →